Fabio Didonè

Dr. Fabio Didonè


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LBLaura Botta
Laura Botta
Gemma GattaGemma Gatta
Gemma Gatta
FDFabio Didonè
Fabio Didonè
ACAngela Lopez Cortes
Angela Lopez Cortes
KPKathy Pritchard-Jones
Kathy Pritchard-Jones
TGthe BENCHISTA Project Working Group
the BENCHISTA Project Working Group
Background: Several studies have shown significant variation in overall survival rates from childhood cancer between countries, using population-based cancer registry (PBCR) data for all cancers combined and for many individual tumour types among children. Without accurate and comparable data on Tumour stage at diagnosis, it is difficult to define the reasons for these survival differences. This is because measurement systems designed for adult cancers do not apply to children’s cancers and cancer registries often hold limited information on paediatric tumour stage and the data sources used to define it.Aims: The BENCHISTA project aims to test the application of the international consensus “Toronto Staging Guidelines” (TG) for paediatric tumours by European and non-European PBCRs for six common paediatric solid tumours so that reliable comparisons of stage at diagnosis and survival rates by stage can be made to understand any differences. A secondary aim is to test the data availability and completeness of collection of several ‘Toronto’ consensus non-stage prognostic factors, treatment types given, occurrence of relapse/progression and cause of death as a descriptive feasibility study.Methods: PBCRs will use their permitted data access channels to apply the Toronto staging guidelines to all incident cases of six solid childhood cancers (medulloblastoma, osteosarcoma, Ewings sarcoma, rhabdomyosarcoma, neuroblastoma and Wilms tumour) diagnosed in a consecutive three-year period within 2014–2017 in their population. Each registry will provide a de-identified patient-level dataset including tumour stage at diagnosis, with only the contributing registry holding the information that would be needed to re-identify the patients. Where available to the registry, patient-level data on ‘Toronto’ non-stage prognostic factors, treatments given and clinical outcomes (relapse/progression/cause of death) will be included. More than 60 PBCRs have been involved in defining the patient-level dataset items and intend to participate by contributing their population-level data. Tumour-specific on-line training workshops with clinical experts are available to cancer registry staff to assist them in applying the Toronto staging guidelines in a consistent manner. There is also a project-specific help desk for discussion of difficult cases and promotion of the CanStaging online tools, developed through the International Association of Cancer Registries, to further ensure standardisation of data collection. Country-specific stage distribution and observed survival by stage at diagnosis will be calculated for each tumour type to compare survival between countries or large geographical regions.Discussion: This study will be promote and enhance the collection of standardized staging data for childhood cancer by European and non-European population-based cancer registries. Therefore, this project can be seen as a feasibility project of widespread use of Toronto Staging at a population-level by cancer registries, specifying the data sources used and testing how well standardized the processes can be. Variation in tumour stage distribution could be due to real differences, to different diagnostic practices between countries and/or to variability in how cancer registries assign Toronto stage. This work also aims to strengthen working relationships between cancer registries, clinical services and cancer-specific clinical study groups, which is important for improving patient outcomes and stimulating research.

24 October 2024 in European Journal of Cancer
Verified
Journal Article
Open access
AIAlice Indini
Alice Indini
FDFabio Didonè
Fabio Didonè
DMDaniela Massi
Daniela Massi
SPSusana Puig
Susana Puig
JCJordi Rubio Casadevall
Jordi Rubio Casadevall
ATAnnalisa Trama
Annalisa Trama
Cutaneous melanoma (CM) is rare in adolescents and young adults (AYA, 15-39 years at cancer diagnosis) and studies on CM in AYAs are scarce. Our aim is to update CM incidence and survival in European AYAs and to compare incidence and survival both with other age groups and over time. We used the EUROCARE-6 database (108 cancer registries; 29 EU countries), calculating incidence rates (IR) per 100,000 individuals/year in the European population (years of diagnosis: 2006-2013), 5-year relative survival (RS), and 5-year RS conditional to surviving the first year after diagnosis, for the follow-up period 2010-2014 (cases diagnosed in 2006-2013). The IR of CM in AYA was greater in females than in males, standing at 7. CM IR was higher in the limbs and lower in the head and neck (H&N) and trunk in females compared to males. Five-year RS was 94 % in AYA and 80 % in older age groups. Survival was higher in limb than in H&N and trunk CM. The incidence of CM increased more in older age groups than in AYA. CM survival rose over time for all ages. Differences in IR between males and females may be due to different behaviors and CM biology. The increase in survival can be attributed to healthcare improvements, early diagnosis, and locoregional surgical treatments. The incidence trends are reassuring in terms of tumor burden in AYA. Our findings support the idea that CM is more aggressive with increasing age and gender differences partially explain survival differences between age groups.

11 June 2025 in European Journal of Cancer
Verified
Journal Article
Open access
ATAnnalisa Trama
Annalisa Trama
SRSilvia Rossi
Silvia Rossi
DBDamien Bennet
Damien Bennet
CSCharles Stiller
Charles Stiller
KPKeiu Paapsi
Keiu Paapsi
LBLaura Botta
Laura Botta
In Europe, cancer survival rates are high and improving for children (0-14 years) and AYAs (15-39 years). However, AYAs often have worse outcomes than children but better than adults. Using EUROCARE data, this study analyzes 5-year relative survival rates across age groups, highlighting age-specific differences and survival trends over time to address persistent disparities. Data were collected from 95 European population-based cancer registries, covering 57 % of the European population. Analyses included malignant cancers diagnosed between 2006 and 2013. Five-year RS was estimated using the period approach for follow-up between 2010 and 2014. Comparisons between AYAs, children, and adults (40-69 years) were conducted using the Z test for absolute differences. Changes in survival trends over time were analyzed from 2004 to 2013 using the Average Annual Percentage Change (AAPC). AYAs had lower 5-year RS than children for hematologic cancers, particularly acute lymphoblastic leukemia (61 % vs. 90 %) and Ewing sarcoma (51 % vs. 69 %). Survival gaps were smaller for central nervous system tumors, germ cell cancers, and thyroid carcinoma. Compared to adults, AYAs had higher 5-year RS for most cancers, except breast, colon, and prostate cancers. Over time, 5-year RS improved across all age groups, with AYAs showing faster improvement than children but slower progress compared to adults for certain cancers. Age-specific disparities in cancer survival persist despite overall improvements. Tailored treatment approaches, specialized AYA oncology programs and collaboration between pediatric and adult oncologists are crucial to bridging survival gaps and improving outcomes for this population.

5 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
FDFabio Didonè
Fabio Didonè
ATAndrea Tittarelli
Andrea Tittarelli
CTClaudio Tresoldi
Claudio Tresoldi
PCPaolo Contiero
Paolo Contiero
RCRiccardo Capocaccia
Riccardo Capocaccia
BGBENCHISTA-Ita Working Group
BENCHISTA-Ita Working Group
Background: Childhood cancers (CC) are rare and treatable; however, survival rates vary across Europe, with poorer outcomes in Eastern countries. Stage at diagnosis is one of the major prognostic factors. The BENCHISTA-Ita project aims to promote the use of the Toronto Guidelines by population-based cancer registries (PBCR) to standardize stage at diagnosis data collection. In Italy, regional cancer registries ensure data quality, while national clinical registries centralize pediatric cancer data. The aim of the study is to promote the linkage between PBCRs and national clinical registries to enhance data completeness. This study presents the results of linking BENCHISTA-Ita neuroblastoma cases with the Italian Neuroblastoma Registry (RINB) as a pilot study. Methods: The linkage process involved probabilistic matching using R software, considering variables such as sex, year of birth, and residence at diagnosis. The study included 294 neuroblastoma cases from BENCHISTA-Ita and 578 from RINB, diagnosed between 2013 and 2017. Results: Results showed that 272 of 294 BENCHISTA-Ita cases matched with RINB cases, improving the completeness of clinical variables such as stage at diagnosis, N-Myc amplification, and relapse/progression. The linkage increased the completeness of clinical variables in PBCR, such as stage at diagnosis from 81% to 99%, N-Myc from 47% to 86%, and relapse/progression from 68% to 98%. Additionally, the linkage improved RINB’s follow-up completeness from 59% to 97% and added new cases in both PBCR and RINB. Conclusions: This linkage demonstrates the potential to enrich both databases, improving data quality and harmonization of cancer indicators. The study highlights the importance of collaboration between PBCRs and clinical registries to ensure comprehensive data collection and enhance more informative population-based studies. Future efforts will focus on expanding the linkage to other national clinical registries.

19 April 2025 in European Journal of Cancer
Verified
Journal Article
Open access
LBLaura Botta
Laura Botta
RCRiccardo Capocaccia
Riccardo Capocaccia
CVClaudia Vener
Claudia Vener
ABAlice Bernasconi
Alice Bernasconi
ATAnnalisa Trama
Annalisa Trama
VJValerie Jooste
Valerie Jooste
Adolescents and young adults (AYAs), aged 15-39, face unique challenges as cancer survivors, including long-term health issues treatment. This study applies a novel approach to estimate the relative risk (RR) of mortality from non-cancer causes in AYA cancer patients compared to the general population and the cure fraction (CF) for AYA patients. Conventional and new mixture cure models with various parametric survival functions were applied to the most common AYA cancers. EUROCARE-6 cases diagnosed between 1998 and 2002, with follow-up to 2014, were selected. Qualitative and quantitative criteria were used to select the optimal model. CFs and RRs were estimated by cancer type, age group, and sex. RRs> 1 were found in both sexes for leukaemia, chronic myeloid leukaemia, lymphoma, central nervous system (CNS) tumours, and skin melanoma, and for testicular germ cell, breast and cervix cancers, with RR generally higher in younger patients and decreasing with age. For acute myeloid leukaemia, colorectal cancer, bone sarcoma for both sexes and soft tissue sarcoma, acute lymphoblastic leukaemia (ALL), and ovary germ cell in females, there was no indication for extra risk. Higher CFs were found in adolescents compared to older AYAs (30-39 years), especially for ALL, CNS tumours in males, and colorectal cancer in females. Further studies are needed to understand why RRs are elevated in AYA patients, to investigate comorbidities and side effects of treatment. Accurate estimation of cancer mortality and CF is vital for resource allocation, tailored follow-up care, and imporving patient quality of life.

10 February 2025 in European Journal of Cancer
Verified
Journal Article
Open access
AIAlice Indini
Alice Indini
FDFabio Didonè
Fabio Didonè
DMDaniela Massi
Daniela Massi
SPSusana Puig
Susana Puig
JCJordi Rubio Casadevall
Jordi Rubio Casadevall
ATAnnalisa Trama
Annalisa Trama